Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BriaCell Therapeutics Corp.

Get SEC filing alerts via email and in your feed for BriaCell Therapeutics Corp.

BCTX BCTXW BCTXZ

BriaCell Therapeutics Corp.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer, primarily metastatic breast cancer. Its lead product, Bria-IMT™, is a genetically engineered whole-cell immunotherapy designed to activate the immune system against tumors, often combined with immune checkpoint inhibitors. The company also develops personalized off-the-shelf immunotherapies for multiple cancers. BriaCell relies on third-party manufacturing and targets oncologists and cancer treatment centers globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BriaCell Therapeutics Corp.

1
1
BriaCell Therapeutics Corp. BriaCell Therapeutics Reports $7.3 Million Net Loss in Q2 2026, Cash Reserves Increase to $29.9 Million

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
BriaCell Therapeutics Corp. BriaCell Therapeutics Reports Increased Net Loss and Rising R&D Expenses in Latest Quarter

Via official filing (AI summary) | 6 months ago | 0 comments

3
1
BriaCell Therapeutics Corp. BriaCell Therapeutics Reports Increased Losses and Advances Phase 3 Trial for Bria-IMT™

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
BriaCell Therapeutics Corp. BriaCell Therapeutics Reports Financial Growth and Ongoing Losses in Latest 10-Q Filing

Via official filing (AI summary) | 12 months ago | 0 comments

5
1
BriaCell Therapeutics Corp. BriaCell Therapeutics Reports Financial Growth and Strategic Advancements in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BriaCell Therapeutics Corp. BriaCell Therapeutics Reports Financial Developments and Clinical Advancements in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments